Biomarkers of protein oxidation in human disease

Current Molecular Medicine

Volumn 12, Issue 6, 2012, Pages 681-697

  Garcia Garcia, A ^a   Rodriguez Rocha, H ^a   Madayiputhiya, N ^a   Pappa, A ^b   Panayiotidis, M I ^c   Franco, R ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Alzheimer's disease; Cancer; Neurodegenerative diseases; Oxidative post translational modifications; Oxidative protein damage; Oxidative stress; Parkinson's disease; Reactive oxygen species; Redox proteomics; Redox signaling; RNS; ROS

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; APOPTOSIS SIGNAL REGULATING KINASE 1; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CYCLOOXYGENASE 1; CYSTEINE; CYTOCHROME C OXIDASE; CYTOCHROME P450; DNA; FLICE INHIBITORY PROTEIN; GLUTAREDOXIN; GLUTATHIONE; HYPOCHLOROUS ACID; METHIONINE; METHIONINE SULFONE; METHIONINE SULFOXIDE REDUCTASE; MYELOPEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXIDASE; PEROXIREDOXIN; PEROXYNITRITE; PROTEIN BCL 2; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; S NITROSOTHIOL; TYROSINE;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CEREBROSPINAL FLUID; CHLORINATION; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE COURSE; DNA STRAND BREAKAGE; HUMAN; MITOCHONDRION; NITRATION; NITROSYLATION; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN CARBONYLATION; PROTEIN CLEAVAGE; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEINS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84862541962     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412800792543     Document Type: Article

References (299)

1. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
2. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-91.
3. Quinn MT, Ammons MC, Deleo FR. The expanding role of NADPH oxidases in health and disease: no longer just agents of death and destruction. Clin Sci (Lond) 2006; 111: 1-20.
4. Ushio-Fukai M. Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 2009; 11: 1289-99.
5. Garrison WM, Jayko ME, Bennett W. Radiation-induced oxidation of protein in aqueous solution. Radiat Res 1962; 16: 483-502.
6. Schuessler H, Schilling K. Oxygen effect in the radiolysis of proteins. Part 2. Bovine serum albumin. Int J Radiat Biol Relat Stud Phys Chem Med 1984; 45: 267-81.
7. Swallow AJ. Radiation chemistry of organic compounds. Oxford; New York: Pergamon Press; 1960.
8. Dattilo JB, Makhoul RG. The role of nitric oxide in vascular biology and pathobiology. Ann Vasc Surg 1997; 11: 307-14.
9. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004; 287: C817-33.
10. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
11. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181-9.
12. Brown DI, Griendling KK. Nox proteins in signal transduction. Free Radic Biol Med 2009; 47: 1239-53.
13. Michelson AM, Durosay P. Hemolysis of human erythrocytes by activated oxygen species. Photochem Photobiol 1977; 25: 55-63.
14. Heckl K. Isolation of cDNAs encoding human manganese superoxide dismutase. Nucleic Acids Res 1988; 16: 6224.
15. Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995; 11: 376-81.
16. McCord JM, Fridovich I. The utility of superoxide dismutase in studying free radical reactions. I. Radicals generated by the interaction of sulfite, dimethyl sulfoxide, and oxygen. J Biol Chem 1969; 244: 6056-63.
17. Hjalmarsson K, Marklund SL, Engstrom A, Edlund T. Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase. Proc Natl Acad Sci USA 1987; 84: 6340-4.
18. Adachi T, Ohta H, Yamada H, et al. Quantitative analysis of extracellular-superoxide dismutase in serum and urine by ELISA with monoclonal antibody. Clin Chim Acta 1992; 212: 89-102.
19. Oshino N, Oshino R, Chance B. The characteristics of the peroxidatic reaction of catalase in ethanol oxidation. Biochem J 1973; 131: 555-63.
20. Keilin D, Hartree EF. Properties of azide-catalase. Biochem J 1945; 39: 148-57.
21. Radi R, Turrens JF, Chang LY, et al. Detection of catalase in rat heart mitochondria. J Biol Chem 1991; 266: 22028-34.
22. Salvi M, Battaglia V, Brunati AM, et al. Catalase takes part in rat liver mitochondria oxidative stress defense. J Biol Chem 2007; 282: 24407-15.
23. Park SG, Cha MK, Jeong W, Kim IH. Distinct physiological functions of thiol peroxidase isoenzymes in Saccharomyces cerevisiae. J Biol Chem 2000; 275: 5723-32.
24. Godon C, Lagniel G, Lee J, et al. The H2O2 stimulon in Saccharomyces cerevisiae. J Biol Chem 1998; 273: 22480-9.
25. Lee SR, Kim JR, Kwon KS, et al. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem 1999; 274: 4722-34.
26. Chae HZ, Chung SJ, Rhee SG. Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem 1994; 269: 27670-8.
27. Netto LES, Chae HZ, Kang SW, Rhee SG, Stadtman ER. Removal of hydrogen peroxide by thiol-specific antioxidant enzyme (TSA) is involved with its antioxidant properties. TSA possesses thiol peroxidase activity. J Biol Chem 1996; 271: 15315-21.
28. Flohe L, Gunzler WA, Schock HH. Glutathione peroxidase: a selenoenzyme. FEBS Lett 1973; 32: 132-4.
29. Omaye ST, Tappel AL. Effect of cadmium chloride on the rat testicular soluble selenoenzyme, glutathione peroxidase. Res Commun Chem Pathol Pharmacol 1975; 12: 695-711.
30. Beutler E. Nutritional and metabolic aspects of glutathione. Annu Rev Nutr 1989; 9: 287-302.
31. Jain A, Martensson J, Stole E, Auld PA, Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 1991; 88: 1913-7.
32. Franco R, Cidlowski JA. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 2009; 16: 1303-14.
33. Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI. The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem 2007; 113: 234-58.
34. Esterbauer H, Dieber-Rotheneder M, Striegl G, Waeg G. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 1991; 53: 314S-21S.
35. Sies H, Stahl W. Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Am J Clin Nutr 1995; 62: 1315S-21S.
36. Takahashi MA, Asada K. Superoxide anion permeability of phospholipid membranes and chloroplast thylakoids. Arch Biochem Biophys 1983; 226: 558-66.
37. Lynch RE, Fridovich I. Permeation of the erythrocyte stroma by superoxide radical. J Biol Chem 1978; 253: 4697-9.
38. Ramasarma T. Generation of H2O in biomembranes. Biochim Biophys Acta 1982; 694: 69-93.
39. Zigler JS, Jr., Jernigan HM, Jr., Garland D, Reddy VN. The effects of oxygen radicals generated in the medium on lenses in organ culture: inhibition of damage by chelated iron. Arch Biochem Biophys 1985; 241: 163-72.
40. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 2004; 101: 4003-8.
41. Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic Res Commun 1993; 18: 195-9.
42. Denicola A, Souza JM, Radi R, Lissi E. Nitric oxide diffusion in membranes determined by fluorescence quenching. Arch Biochem Biophys 1996; 328: 208-12.
43. Lancaster JR, Jr. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci U S A 1994; 91: 8137-41.
44. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 1994; 308: 89-95.
45. Botti H, Batthyany C, Trostchansky A, et al. Peroxynitritemediated alpha-tocopherol oxidation in low-density lipoprotein: a mechanistic approach. Free Radic Biol Med 2004; 36: 152-62.
46. Batthyany C, Schopfer FJ, Baker PR, et al. Reversible posttranslational modification of proteins by nitrated fatty acids in vivo. J Biol Chem 2006; 281: 20450-63.
47. Lozano-Juste J, Colom-Moreno R, Leon J. In vivo protein tyrosine nitration in Arabidopsis thaliana. J Exp Bot 2011.
48. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998; 78: 547-81.
49. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997; 272: 20313-6.
50. Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta 2005; 1703: 93-109.
51. Kwong JQ, Beal MF, Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. J Neurochem 2006; 97: 1659-75.
52. Lenaz G, Bovina C, D'Aurelio M, et al. Role of mitochondria in oxidative stress and aging. Ann N Y Acad Sci 2002; 959: 199-213.
53. Sastre J, Pallardo FV, Vina J. The role of mitochondrial oxidative stress in aging. Free Radic Biol Med 2003; 35: 1-8.
54. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev 1998; 30: 225-43.
55. Torres CA, Perez VI. Proteasome modulates mitochondrial function during cellular senescence. Free Radic Biol Med 2008; 44: 403-14.
56. Ding Q, Martin S, Dimayuga E, Bruce-Keller AJ, Keller JN. LMP2 knock-out mice have reduced proteasome activities and increased levels of oxidatively damaged proteins. Antioxid Redox Signal 2006; 8: 130-5.
57. Ding Q, Dimayuga E, Keller JN. Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxid Redox Signal 2006; 8: 163-72.
58. Zeng BY, Medhurst AD, Jackson M, Rose S, Jenner P. Proteasomal activity in brain differs between species and brain regions and changes with age. Mech Ageing Dev 2005; 126: 760-6.
59. Nystrom T. Role of oxidative carbonylation in protein quality control and senescence. EMBO J 2005; 24: 1311-7.
60. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie 2001; 83: 301-10.
61. Keller JN, Huang FF, Dimayuga ER, Maragos WF. Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic Biol Med 2000; 29: 1037-42.
62. Grune T, Reinheckel T, Davies KJ. Degradation of oxidized proteins in mammalian cells. FASEB J 1997; 11: 526-34.
63. Sitte N, Merker K, Von Zglinicki T, Grune T, Davies KJ. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I--effects of proliferative senescence. FASEB J 2000; 14: 2495-502.
64. Sitte N, Merker K, Von Zglinicki T, Davies KJ, Grune T. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part II--aging of nondividing cells. FASEB J 2000; 14: 2503-10.
65. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003; 25: 207-18.
66. Garrison WM. Reaction mechanisms in radiolysis of peptides, polypeptides, and proteins. Chem Rev 1987; 87: 381-98.
67. Uchida K, Kato Y, Kawakishi S. A novel mechanism for oxidative cleavage of prolyl peptides induced by the hydroxyl radical. Biochem Biophys Res Commun 1990; 169: 265-71.
68. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.
69. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
70. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005; 6: 150-66.
71. Hao G, Derakhshan B, Shi L, Campagne F, Gross SS. SNOSID, a proteomic method for identification of cysteine Snitrosylation sites in complex protein mixtures. Proc Natl Acad Sci USA 2006; 103: 1012-7.
72. Ghezzi P. Regulation of protein function by glutathionylation. Free Radic Res 2005; 39: 573-80.
73. Chae HZ, Rhee SG. A thiol-specific antioxidant and sequence homology to various proteins of unknown function. Biofactors 1994; 4: 177-80.
74. Rabilloud T, Heller M, Gasnier F, et al. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem 2002; 277: 19396-401.
75. Hirotsu S, Abe Y, Okada K, et al. Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product. Proc Natl Acad Sci USA 1999; 96: 12333-8.
76. Schroder E, Littlechild JA, Lebedev AA, et al. Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7 A resolution. Structure 2000; 8: 605-15.
77. Cross JV, Templeton DJ. Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the ATP-binding domain. Biochem J 2004; 381: 675-83.
78. Cross JV, Templeton DJ. Thiol oxidation of cell signaling proteins: Controlling an apoptotic equilibrium. J Cell Biochem 2004; 93: 104-11.
79. Ellis HR, Poole LB. Novel application of 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole to identify cysteine sulfenic acid in the AhpC component of alkyl hydroperoxide reductase. Biochemistry 1997; 36: 15013-8.
80. Bryk R, Griffin P, Nathan C. Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature 2000; 407: 211-5.
81. Raftery MJ, Yang Z, Valenzuela SM, Geczy CL. Novel intraand inter-molecular sulfinamide bonds in S100A8 produced by hypochlorite oxidation. J Biol Chem 2001; 276: 33393-401.
82. Boschi-Muller S, Azza S, Sanglier-Cianferani S, et al. A sulfenic acid enzyme intermediate is involved in the catalytic mechanism of peptide methionine sulfoxide reductase from Escherichia coli. J Biol Chem 2000; 275: 35908-13.
83. Poole LB, Karplus PA, Claiborne A. Protein sulfenic acids in redox signaling. Annu Rev Pharmacol Toxicol 2004; 44: 325-47.
84. Biteau B, Labarre J, Toledano MB. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 2003; 425: 980-4.
85. Woo HA, Jeong W, Chang TS, et al. Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem 2005; 280: 3125-8.
86. Chang TS, Jeong W, Woo HA, et al. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 2004; 279: 50994-1001.
87. Klatt P, Lamas S. Regulation of protein function by Sglutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 2000; 267: 4928-44.
88. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, Shelton MD. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal 2008; 10: 1941-88.
89. Beer SM, Taylor ER, Brown SE, et al. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: implications for mitochondrial redox regulation and antioxidant DEFENSE. J Biol Chem 2004; 279: 47939-51.
90. Kharitonov VG, Sundquist AR, Sharma VS. Kinetics of nitrosation of thiols by nitric oxide in the presence of oxygen. J Biol Chem 1995; 270: 28158-64.
91. Wink DA, Nims RW, Darbyshire JF, et al. Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol 1994; 7: 519-25.
92. van der Vliet A, Hoen PA, Wong PS, Bast A, Cross CE. Formation of S-nitrosothiols via direct nucleophilic nitrosation of thiols by peroxynitrite with elimination of hydrogen peroxide. J Biol Chem 1998; 273: 30255-62.
93. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009; 15: 391-404.
94. Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol Med 2003; 9: 160-8.
95. Liu L, Yan Y, Zeng M, et al. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 2004; 116: 617-28.
96. Bhandari V, Choo-Wing R, Chapoval SP, et al. Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. Proc Natl Acad Sci USA 2006; 103: 11021-6.
97. Wu H, Romieu I, Sienra-Monge JJ, et al. Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma. J Allergy Clin Immunol 2007; 120: 322-8.
98. Levine RL, Mosoni L, Berlett BS, Stadtman ER. Methionine residues as endogenous antioxidants in proteins. Proc Natl Acad Sci USA 1996; 93: 15036-40.
99. Hoshi T, Heinemann S. Regulation of cell function by methionine oxidation and reduction. J Physiol 2001; 531: 1-11.
100. Ripp SL, Itagaki K, Philpot RM, Elfarra AA. Methionine Soxidation in human and rabbit liver microsomes: evidence for a high-affinity methionine S-oxidase activity that is distinct from flavin-containing monooxygenase 3. Arch Biochem Biophys 1999; 367: 322-32.
101. Sharov VS, Ferrington DA, Squier TC, Schoneich C. Diastereoselective reduction of protein-bound methionine sulfoxide by methionine sulfoxide reductase. FEBS Lett 1999; 455: 247-50.
102. Dever JT, Elfarra AA. In vivo metabolism of L-methionine in mice: evidence for stereoselective formation of methionine-dsulfoxide and quantitation of other major metabolites. Drug Metab Dispos 2006; 34: 2036-43.
103. Moskovitz J, Weissbach H, Brot N. Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. Proc Natl Acad Sci USA 1996; 93: 2095-9.
104. Jung S, Hansel A, Kasperczyk H, Hoshi T, Heinemann SH. Activity, tissue distribution and site-directed mutagenesis of a human peptide methionine sulfoxide reductase of type B: hCBS1. FEBS Lett 2002; 527: 91-4.
105. Lin Z, Johnson LC, Weissbach H, et al. Free methionine-(R)-sulfoxide reductase from Escherichia coli reveals a new GAF domain function. Proc Natl Acad Sci USA 2007; 104: 9597-602.
106. Le DT, Lee BC, Marino SM, et al. Functional analysis of free methionine-R-sulfoxide reductase from Saccharomyces cerevisiae. J Biol Chem 2009; 284: 4354-64.
107. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992; 298: 431-7.
108. Beckman JS, Ischiropoulos H, Zhu L, et al. Kinetics of superoxide dismutase-and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 1992; 298: 438-45.
109. Gow A, Duran D, Thom SR, Ischiropoulos H. Carbon dioxide enhancement of peroxynitrite-mediated protein tyrosine nitration. Arch Biochem Biophys 1996; 333: 42-8.
110. Thomas DD, Espey MG, Vitek MP, Miranda KM, Wink DA. Protein nitration is mediated by heme and free metals through Fenton-type chemistry: an alternative to the NO/O2-reaction. Proc Natl Acad Sci USA 2002; 99: 12691-6.
111. Pfeiffer S, Mayer B. Lack of tyrosine nitration by peroxynitrite generated at physiological pH. J Biol Chem 1998; 273: 27280-5.
112. Pfeiffer S, Schmidt K, Mayer B. Dityrosine formation outcompetes tyrosine nitration at low steady-state concentrations of peroxynitrite. Implications for tyrosine modification by nitric oxide/superoxide in vivo. J Biol Chem 2000; 275: 6346-52.
113. Brennan ML, Wu W, Fu X, et al. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J Biol Chem 2002; 277: 17415-27.
114. Gunther MR, Hsi LC, Curtis JF, et al. Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation. J Biol Chem 1997; 272: 17086-90.
115. Amici A, Levine RL, Tsai L, Stadtman ER. Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalyzed oxidation reactions. J Biol Chem 1989; 264: 3341-6.
116. Requena JR, Chao CC, Levine RL, Stadtman ER. Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. Proc Natl Acad Sci USA 2001; 98: 69-74.
117. Moore K, Roberts LJ, 2nd. Measurement of lipid peroxidation. Free Radic Res 1998; 28: 659-71.
118. Remmer H HT, Frańk H, Müh-Zange M. Cytochrome P-450 oxidation of alkanes originating as scission products during lipid peroxidation. Xenobiotica 1984; 14: 207-19.
119. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003; 42: 318-43.
120. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 2000; 28: 1685-96.
121. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
122. Schneider C, Tallman KA, Porter NA, Brash AR. Two distinct pathways of formation of 4-hydroxynonenal. Mechanisms of nonenzymatic transformation of the 9-and 13-hydroperoxides of linoleic acid to 4-hydroxyalkenals. J Biol Chem 2001; 276: 20831-8.
123. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-7.
124. L. Jackson Roberts IaJDM. Measurement of F2-Isoprostanes as an index of oxidative stress in vivo. Free Radical Biology & Medicine 1999; 28: 505-13.
125. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ, 2nd. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992; 89: 10721-5.
126. Refsgaard HH, Tsai L, Stadtman ER. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 2000; 97: 611-6.
127. Grimsrud PA, Xie H, Griffin TJ, Bernlohr DA. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 2008; 283: 21837-41.
128. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003; 9: 169-76.
129. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
130. Kristal BS, Yu BP. An emerging hypothesis: synergistic induction of aging by free radicals and Maillard reactions. J Gerontol 1992; 47: B107-14.
131. Harrison JE, Schultz J. Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 1976; 251: 1371-4.
132. Jerlich A, Tschabuschnig S, Fabjan JS, Schaur RJ. Kinetics of chlorination of monochlorodimedone by myeloperoxidase. Int J Clin Lab Res 2000; 30: 33-7.
133. Winterbourn CC. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim Biophys Acta 1985; 840: 204-10.
134. Hawkins CL, Davies MJ. Hypochlorite-induced damage to proteins: formation of nitrogen-centred radicals from lysine residues and their role in protein fragmentation. Biochem J 1998; 332 (Pt 3): 617-25.
135. Knox WE, Stumpf PK, et al. The inhibition of sulfhydryl enzymes as the basis of the bactericidal action of chlorine. J Bacteriol 1948; 55: 451-8.
136. Pattison DI, Davies MJ. Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. Chem Res Toxicol 2001; 14: 1453-64.
137. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991; 266: 11649-53.
138. Verzijl N, DeGroot J, Oldehinkel E, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000; 350 Pt 2: 381-7.
139. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995; 34: 3702-9.
140. Uchida K, Stadtman ER. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra-and intermolecular cross-linking reaction. J Biol Chem 1993; 268: 6388-93.
141. Friguet B, Stadtman ER, Szweda LI. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J Biol Chem 1994; 269: 21639-43.
142. Hulka BS, Wilcosky T. Biological markers in epidemiologic research. Arch Environ Health 1988; 43: 83-9.
143. Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 2003; 3: 525-9.
144. Perera FP, Weinstein IB. Molecular epidemiology: recent advances and future directions. Carcinogenesis 2000; 21: 517-24.
145. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx 2004; 1: 182-8.
146. Ioannidis PAOAP, MD. Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses. JAMA 2011; 305: 2200-10.
147. Schulte PA. Biomarkers in epidemiology: scientific issues and ethical implications. Environ Health Perspect 1992; 98: 143-7.
148. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest 2001; 120: 2035-46.
149. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-47.
150. Butterfield DA, Howard BJ, LaFontaine MA. Brain oxidative stress in animal models of accelerated aging and the agerelated neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr Med Chem 2001; 8: 815-28.
151. Markesbery WR, Lovell MA. DNA oxidation in Alzheimer's disease. Antioxid Redox Signal 2006; 8: 2039-45.
152. Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006; 8: 2021-37.
153. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 2004; 38: 105-22.
154. Orhan H, van Holland B, Krab B, et al. Evaluation of a multiparameter biomarker set for oxidative damage in man: increased urinary excretion of lipid, protein and DNA oxidation products after one hour of exercise. Free Radic Res 2004; 38: 1269-79.
155. Tamura S, Tsukahara H, Ueno M, et al. Evaluation of a urinary multi-parameter biomarker set for oxidative stress in children, adolescents and young adults. Free Radic Res 2006; 40: 1198-205.
156. Ptolemy AS, Lee R, Britz-McKibbin P. Strategies for comprehensive analysis of amino acid biomarkers of oxidative stress. Amino Acids 2007; 33: 3-18.
157. Carini M, Aldini G, Facino RM. Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins. Mass Spectrom Rev 2004; 23: 281-305.
158. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003; 329: 23-38.
159. Pignatelli B, Li CQ, Boffetta P, et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001; 61: 778-84.
160. Rossner P, Jr., Terry MB, Gammon MD, et al. Plasma protein carbonyl levels and breast cancer risk. J Cell Mol Med 2007; 11: 1138-48.
161. Hensley K, Hall N, Subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995; 65: 2146-56.
162. Smith MA, Sayre LM, Anderson VE, et al. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 1998; 46: 731-5.
163. Alam ZI, Daniel SE, Lees AJ, et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997; 69: 1326-9.
164. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998; 70: 268-75.
165. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
166. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006; 52: 601-23.
167. Dalle-Donne I, Scaloni A, Giustarini D, et al. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 2005; 24: 55-99.
168. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
169. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 2010; 38: 96-109.
170. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991; 51: 794-8.
171. Laurent A, Nicco C, Chereau C, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948-56.
172. Arnold RS, Shi J, Murad E, et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 5550-5.
173. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006; 25: 4647-62.
174. Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 29: 4080-90.
175. Szeto SS, Reinke SN, Sykes BD, Lemire BD. Ubiquinonebinding site mutations in the Saccharomyces cerevisiae succinate dehydrogenase generate superoxide and lead to the accumulation of succinate. The Journal of biological chemistry 2007; 282: 27518-26.
176. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxiainducible factor activation and tumorigenesis. Mol Cell Biol 2008; 28: 718-31.
177. Slane BG, Aykin-Burns N, Smith BJ, et al. Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res 2006; 66: 7615-20.
178. Ishii N, Ishii T, Hartman PS. The role of the electron transport SDHC gene on lifespan and cancer. Mitochondrion 2007; 7: 24-8.
179. Olson SY, Garban HJ. Regulation of apoptosis-related genes by nitric oxide in cancer. Nitric Oxide 2008; 19: 170-6.
180. Ridnour LA, Thomas DD, Donzelli S, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006; 8: 1329-37.
181. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-34.
182. Wang L, Shi GG, Yao JC, et al. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 2005; 8: 18-28.
183. Lahdenranta J, Hagendoorn J, Padera TP, et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 2009; 69: 2801-8.
184. Qiu H, Orr FW, Jensen D, et al. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am J Pathol 2003; 162: 403-12.
185. Tanriover N, Ulu MO, Isler C, et al. Neuronal nitric oxide synthase expression in glial tumors: correlation with malignancy and tumor proliferation. Neurol Res 2008; 30: 940-4.
186. Cascorbi I, Henning S, Brockmoller J, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene. Cancer Res 2000; 60: 644-9.
187. Ahn J, Gammon MD, Santella RM, et al. Myeloperoxidase genotype, fruit and vegetable consumption, and breast cancer risk. Cancer Res 2004; 64: 7634-9.
188. Ambrosone CB, Ahn J, Singh KK, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 2005; 65: 1105-11.
189. Narko K, Ristimaki A, MacPhee M, et al. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. The Journal of biological chemistry 1997; 272: 21455-60.
190. Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002; 55: 429-34.
191. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010; 16: 1384-90.
192. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 2006; 43: 143-81.
193. Roshchupkina GI, Bobko AA, Bratasz A, et al. In vivo EPR measurement of glutathione in tumor-bearing mice using improved disulfide biradical probe. Free Radic Biol Med 2008; 45(3): 312-20.
194. Navarro J, Obrador E, Carretero J, et al. Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic Biol Med 1999; 26: 410-8.
195. Oltra AM, Carbonell F, Tormos C, Iradi A, Saez GT. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med 2001; 30: 1286-92.
196. el-Sharabasy MM, el-Dosoky I, Horria H, Khalaf AH. Elevation of glutathione, glutathione-reductase and nucleic acids in both normal tissues and tumour of breast cancer patients. Cancer Lett 1993; 72: 11-5.
197. Di Ilio C, Sacchetta P, Angelucci S, et al. Glutathione peroxidase and glutathione reductase activities in cancerous and non-cancerous human kidney tissues. Cancer Lett 1995; 91: 19-23.
198. Esworthy RS, Baker MA, Chu FF. Expression of seleniumdependent glutathione peroxidase in human breast tumor cell lines. Cancer Res 1995; 55: 957-62.
199. Hasegawa Y, Takano T, Miyauchi A, et al. Decreased expression of glutathione peroxidase mRNA in thyroid anaplastic carcinoma. Cancer Lett 2002; 182: 69-74.
200. Xu Y, Fang F, Dhar SK, et al. Mutations in the SOD2 promoter reveal a molecular basis for an activating protein 2-dependent dysregulation of manganese superoxide dismutase expression in cancer cells. Mol Cancer Res 2008; 6: 1881-93.
201. Wang LI, Miller DP, Sai Y, et al. Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst 2001; 93: 1818-21.
202. Ergen HA, Narter F, Timirci O, Isbir T. Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study. Anticancer Res 2007; 27: 1227-30.
203. Wheatley-Price P, Asomaning K, Reid A, et al. Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. Cancer 2008; 112: 1037-42.
204. Zhang HJ, Yan T, Oberley TD, Oberley LW. Comparison of effects of two polymorphic variants of manganese superoxide dismutase on human breast MCF-7 cancer cell phenotype. Cancer Res 1999; 59: 6276-83.
205. Kinnula VL, Torkkeli T, Kristo P, et al. Ultrastructural and chromosomal studies on manganese superoxide dismutase in malignant mesothelioma. Am J Respir Cell Mol Biol 2004; 31: 147-53.
206. Cobbs CS, Levi DS, Aldape K, Israel MA. Manganese superoxide dismutase expression in human central nervous system tumors. Cancer Res 1996; 56: 3192-5.
207. Yeung BH, Wong KY, Lin MC, et al. Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2. Br J Cancer 2008; 99: 283-93.
208. Kuninaka S, Ichinose Y, Koja K, Toh Y. Suppression of manganese superoxide dismutase augments sensitivity to radiation, hyperthermia and doxorubicin in colon cancer cell lines by inducing apoptosis. Br J Cancer 2000; 83: 928-34.
209. Suresh A, Guedez L, Moreb J, Zucali J. Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment. Br J Haematol 2003; 120: 457-63.
210. Mantymaa P, Siitonen T, Guttorm T, et al. Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol 2000; 108: 574-81.
211. Hur GC, Cho SJ, Kim CH, et al. Manganese superoxide dismutase expression correlates with chemosensitivity in human gastric cancer cell lines. Clin Cancer Res 2003; 9: 5768-75.
212. Hirose K, Longo DL, Oppenheim JJ, Matsushima K. Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEB J 1993; 7: 361-8.
213. Connor KM, Hempel N, Nelson KK, et al. Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res 2007; 67: 10260-7.
214. Nelson KK, Ranganathan AC, Mansouri J, et al. Elevated sod2 activity augments matrix metalloproteinase expression: evidence for the involvement of endogenous hydrogen peroxide in regulating metastasis. Clin Cancer Res 2003; 9: 424-32.
215. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-5.
216. Zhang B, Wang Y, Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 2009; 286: 154-60.
217. Yanagawa T, Ishikawa T, Ishii T, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 1999; 145: 127-32.
218. Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 2000; 156: 27-35.
219. Chang JW, Jeon HB, Lee JH, et al. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 2001; 289: 507-12.
220. Kim JH, Bogner PN, Baek SH, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res 2008; 14: 2326-33.
221. Kim K, Yu M, Han S, et al. Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep 2009; 21: 1391-6.
222. Noh DY, Ahn SJ, Lee RA, et al. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 2001; 21: 2085-90.
223. Kinnula VL, Lehtonen S, Sormunen R, et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 2002; 196: 316-23.
224. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003; 9: 3418-24.
225. Chang XZ, Li DQ, Hou YF, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007; 9: R76.
226. Jarvela S, Rantala I, Rodriguez A, et al. Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors. BMC Cancer 2010; 10: 104.
227. Sedelnikova OA, Redon CE, Dickey JS, et al. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res 2010; 704: 152-9.
228. Nowsheen S, Wukovich RL, Aziz K, et al. Accumulation of oxidatively induced clustered DNA lesions in human tumor tissues. Mutat Res 2009; 674: 131-6.
229. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 2011; 711: 193-201.
230. Azad N, Iyer AK, Wang L, et al. Nitric oxide-mediated bcl-2 stabilization potentiates malignant transformation of human lung epithelial cells. Am J Respir Cell Mol Biol 2010; 42: 578-85.
231. Azad N, Vallyathan V, Wang L, et al. S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. J Biol Chem 2006; 281: 34124-34.
232. Chanvorachote P, Nimmannit U, Lu Y, et al. Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1. J Biol Chem 2009; 284: 28476-84.
233. Chanvorachote P, Nimmannit U, Stehlik C, et al. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res 2006; 66: 6353-60.
234. Chanvorachote P, Nimmannit U, Wang L, et al. Nitric oxide negatively regulates Fas CD95-induced apoptosis through inhibition of ubiquitin-proteasome-mediated degradation of FLICE inhibitory protein. J Biol Chem 2005; 280: 42044-50.
235. Iyer AK, Azad N, Wang L, Rojanasakul Y. Role of Snitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide 2008; 19: 146-51.
236. Torok NJ, Higuchi H, Bronk S, Gores GJ. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. Cancer Res 2002; 62: 1648-53.
237. Park HS, Yu JW, Cho JH, et al. Inhibition of apoptosis signalregulating kinase 1 by nitric oxide through a thiol redox mechanism. J Biol Chem 2004; 279: 7584-90.
238. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000.
239. Rahman MA, Senga T, Ito S, et al. S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. J Biol Chem 2010; 285: 3806-14.
240. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440-50.
241. Velu CS, Niture SK, Doneanu CE, Pattabiraman N, Srivenugopal KS. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry 2007; 46: 7765-80.
242. Yusuf MA, Chuang T, Bhat GJ, Srivenugopal KS. Cys-141 glutathionylation of human p53: Studies using specific polyclonal antibodies in cancer samples and cell lines. Free Radic Biol Med 2010; 49: 908-17.
243. Schonhoff CM, Daou MC, Jones SN, Schiffer CA, Ross AH. Nitric oxide-mediated inhibition of Hdm2-p53 binding. Biochemistry 2002; 41: 13570-4.
244. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science 2010; 330: 517-21.
245. Guo Z, Deshpande R, Paull TT. ATM activation in the presence of oxidative stress. Cell Cycle 2010; 9: 4805-11.
246. Tang CH, Wei W, Liu L. Regulation of DNA repair by Snitrosylation. Biochim Biophys Acta 2011;
247. Wei W, Li B, Hanes MA, et al. S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med 2010; 2: 19ra3.
248. Wei W, Yang Z, Tang CH, Liu L. Targeted deletion of GSNOR in hepatocytes of mice causes nitrosative inactivation of O6-alkylguanine-DNA alkyltransferase and increased sensitivity to genotoxic diethylnitrosamine. Carcinogenesis 2011; 32: 973-7.
249. Yilmaz IA, Akcay T, Cakatay U, et al. Relation between bladder cancer and protein oxidation. Int Urol Nephrol 2003; 35: 345-50.
250. Morabito F, Cristani M, Saija A, et al. Lipid peroxidation and protein oxidation in patients affected by Hodgkin's lymphoma. Mediators Inflamm 2004; 13: 381-3.
251. Tanriverdi T, Hanimoglu H, Kacira T, et al. Glutathione peroxidase, glutathione reductase and protein oxidation in patients with glioblastoma multiforme and transitional meningioma. J Cancer Res Clin Oncol 2007; 133: 627-33.
252. Mannello F, Tonti GA, Medda V. Protein oxidation in breast microenvironment: Nipple aspirate fluid collected from breast cancer women contains increased protein carbonyl concentration. Cell Oncol 2009; 31: 383-92.
253. Huang Z, Komninou D, Kleinman W, et al. Enhanced levels of glutathione and protein glutathiolation in rat tongue epithelium during 4-NQO-induced carcinogenesis. Int J Cancer 2007; 120: 1396-401.
254. MacMillan-Crow LA, Greendorfer JS, Vickers SM, Thompson JA. Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma. Arch Biochem Biophys 2000; 377: 350-6.
255. Wang TC, Jan KY, Wang AS, Gurr JR. Trivalent arsenicals induce lipid peroxidation, protein carbonylation, and oxidative DNA damage in human urothelial cells. Mutat Res 2007; 615: 75-86.
256. Perluigi M, Di Domenico F, Blarzino C, et al. Effects of UVBinduced oxidative stress on protein expression and specific protein oxidation in normal human epithelial keratinocytes: a proteomic approach. Proteome Sci 2010; 8: 13.
257. Colombo G, Aldini G, Orioli M, et al. Water-Soluble alpha,beta-unsaturated aldehydes of cigarette smoke induce carbonylation of human serum albumin. Antioxid Redox Signal 2010; 12: 349-64.
258. Lin CC, Su TH, Wang TS. Protein carbonylation in THP-1 cells induced by cigarette smoke extract via a coppercatalyzed pathway. Chem Res Toxicol 2009; 22: 1232-8.
259. Mattagajasingh SN, Misra BR, Misra HP. Carcinogenic chromium(VI)-induced protein oxidation and lipid peroxidation: implications in DNA-protein crosslinking. J Appl Toxicol 2008; 28: 987-97.
260. Kadirvel R, Sundaram K, Mani S, et al. Supplementation of ascorbic acid and alpha-tocopherol prevents arsenic-induced protein oxidation and DNA damage induced by arsenic in rats. Hum Exp Toxicol 2007; 26: 939-46.
261. Ogasawara Y, Ishii K. Exposure to chrysotile asbestos causes carbonylation of glucose 6-phosphate dehydrogenase through a reaction with lipid peroxidation products in human lung epithelial cells. Toxicol Lett 2010; 195: 1-8.
262. Muscat JE, Kleinman W, Colosimo S, et al. Enhanced protein glutathiolation and oxidative stress in cigarette smokers. Free Radic Biol Med 2004; 36: 464-70.
263. Yeh CC, Lai CY, Hsieh LL, et al. Protein carbonyl levels, glutathione S-transferase polymorphisms and risk of colorectal cancer. Carcinogenesis 2010; 31: 228-33.
264. Bahar G, Feinmesser R, Shpitzer T, Popovtzer A, Nagler RM. Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer 2007; 109: 54-9.
265. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
266. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003; 60: 1696-702.
267. Donnelly PS, Xiao Z, Wedd AG. Copper and Alzheimer's disease. Curr Opin Chem Biol 2007; 11: 128-33.
268. Huang X, Atwood CS, Hartshorn MA, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38: 7609-16.
269. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007; 43: 658-77.
270. Vina J, Lloret A, Valles SL, et al. Mitochondrial oxidant signalling in Alzheimer's disease. J Alzheimers Dis 2007; 11: 175-81.
271. Jana A, Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J Biol Chem 2004; 279: 51451-9.
272. Sultana R, Mecocci P, Mangialasche F, et al. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis 2011; 24: 77-84.
273. Aoyama K, Matsubara K, Fujikawa Y, et al. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol 2000; 47: 524-7.
274. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 2002; 293: 1566-70.
275. Ahmed N, Ahmed U, Thornalley PJ, et al. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2005; 92: 255-63.
276. Yoshida Y, Yoshikawa A, Kinumi T, et al. Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimer's disease patients and their potential as biomarkers. Neurobiol Aging 2009; 30: 174-85.
277. Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain 2004; 127: 1693-705.
278. Rodgers KJ, Hume PM, Morris JG, Dean RT. Evidence for Ldopa incorporation into cell proteins in patients treated with levodopa. J Neurochem 2006; 98: 1061-7.
279. Chinta SJ, Rajagopalan S, Butterfield DA, Andersen JK. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci Lett 2006; 402: 137-41.
280. Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 2005; 7: 685-93.
281. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7: 97-109.
282. Sherer TB, Greenamyre JT. Oxidative damage in Parkinson's disease. Antioxid Redox Signal 2005; 7: 627-9.
283. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 2008; 9: 505-18.
284. Su B, Wang X, Zheng L, et al. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta 2010; 1802: 135-42.
285. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008; 4: 600-9.
286. Sherer TB, Richardson JR, Testa CM, et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 2007; 100: 1469-79.
287. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005; 2: 484-94.
288. Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 2007; 11: 151-67.
289. Cannon JR, Greenamyre JT. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res 2010; 184: 17-33.
290. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283: 9089-100.
291. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823-7.
292. Parker WD, Jr., Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719-23.
293. Ilic TV, Jovanovic M, Jovicic A, Tomovic M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 1999; 14: 141-7.
294. Pennathur S, Heinecke JW. Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Front Biosci 2004; 9: 565-74.
295. Rosen P, Nawroth PP, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212.
296. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563-74.
297. Constantin A, Constantinescu E, Dumitrescu M, Calin A, Popov D. Effects of ageing on carbonyl stress and antioxidant defense in RBCs of obese Type 2 diabetic patients. J Cell Mol Med 2005; 9: 683-91.
298. Pandey KB, Mishra N, Rizvi SI. Protein oxidation biomarkers in plasma of type 2 diabetic patients. Clin Biochem 2010; 43: 508-11.
299. Brock JW, Jenkins AJ, Lyons TJ, et al. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 2008; 49: 847-55.